AKBA

Akebia Ther

AKBA, USA

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090 for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

https://www.akebia.com

Stock Price

$0.00

0%

increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
AKBA
stock
AKBA

Stock Recap: Is AKBA part of any major index - July 2025 Drop Watch & Safe Investment Capital Preservation Plans baoquankhu1.vn

Read more →
AKBA
stock
AKBA

Retail Surge: How much upside does AKBA have - July 2025 Review & Consistent Profit Focused Trading Strategies baoquankhu1.vn

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$5.4

Analyst Picks

Strong Buy

3

Buy

1

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Neutral

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

9.04

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

1.30 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

0.15 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

47.69 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

7.76

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 48.09% of the total shares of Akebia Ther

1.

BlackRock Inc

(6.9298%)

since

2025/06/30

2.

Vanguard Group Inc

(5.5107%)

since

2025/06/30

3.

State Street Corp

(3.0161%)

since

2025/06/30

4.

Vanguard Total Stock Mkt Idx Inv

(2.9389%)

since

2025/07/31

5.

Geode Capital Management, LLC

(2.291%)

since

2025/06/30

6.

iShares Russell 2000 ETF

(2.2871%)

since

2025/08/31

7.

Morgan Stanley - Brokerage Accounts

(2.0139%)

since

2025/06/30

8.

Renaissance Technologies Corp

(1.5819%)

since

2025/06/30

9.

Goldman Sachs Group Inc

(1.4837%)

since

2025/06/30

10.

SPDR® S&P Biotech ETF

(1.1669%)

since

2025/08/31

11.

MPM Oncology Impact Management LP

(1.0896%)

since

2025/06/30

12.

Nuveen, LLC

(1.0216%)

since

2025/06/30

13.

Franklin Resources Inc

(1.006%)

since

2025/06/30

14.

Vanguard Institutional Extnd Mkt Idx Tr

(0.9781%)

since

2025/07/31

15.

Fidelity Small Cap Index

(0.944%)

since

2025/06/30

16.

Citadel Advisors Llc

(0.874%)

since

2025/06/30

17.

Millennium Management LLC

(0.816%)

since

2025/06/30

18.

Northern Trust Corp

(0.8053%)

since

2025/06/30

19.

Nantahala Capital Management, LLC

(0.7543%)

since

2025/06/30

20.

Great Point Partners LLC

(0.749%)

since

2025/06/30

21.

Foord Global Equity (Lux) A

(0.749%)

since

2025/06/30

22.

iShares Russell 2000 Value ETF

(0.7389%)

since

2025/08/31

23.

Affinity Asset Advisors, LLC

(0.7354%)

since

2025/06/30

24.

Foord Global Equity Class B

(0.6902%)

since

2025/06/30

25.

Nuveen Quant Small Cap Equity R6

(0.6756%)

since

2025/07/31

26.

Qube Research & Technologies

(0.6466%)

since

2025/06/30

27.

JPMorgan Chase & Co

(0.6233%)

since

2025/06/30

28.

Franklin Biotechnology Discv A(acc)USD

(0.6053%)

since

2025/08/31

30.

Fidelity Extended Market Index

(0.4934%)

since

2025/07/31

31.

Jacobs Levy Equity Management, Inc.

(0.4545%)

since

2025/06/30

32.

Vanguard Russell 2000 ETF

(0.4494%)

since

2025/07/31

33.

RTW Biotech Opportunities Ord

(0.4492%)

since

2024/12/31

34.

Franklin Biotechnology Discovery A

(0.3376%)

since

2025/07/31

35.

State St Russell Sm Cap® Indx SL Cl I

(0.3327%)

since

2025/08/31

36.

IMC US Small Cap

(0.2914%)

since

2025/07/31

37.

Vanguard Health Care ETF

(0.2756%)

since

2025/07/31

38.

Fidelity Enhanced Small Cap ETF

(0.2633%)

since

2025/08/29

39.

Schwab Small Cap Index

(0.2407%)

since

2025/07/31

40.

NT R2000 Index Fund - NL

(0.2282%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.044

Latest Release

Date

2025-09-30

EPS Actual

0.002

EPS Estimate

-0.036

EPS Difference

0.038

Surprise Percent

105.5556%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Strong Deep Value(7)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(3)
Economic Moat
Some Competitive Advantage(5.8)
GARP
Fair GARP(5)
Growth
Moderate Growth(5)
Momentum
Moderate Momentum(6)
Net Net
Not Undervalued (Net-Net)(3)
Quality
Low Quality Business(3)
Value
Fair Value(4.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.